Maze Therapeutics Reports Q2 2026 Financial Results

What Happened

• Maze Therapeutics, Inc. (MAZE) filed a Current Report on Form 8-K on August 11, 2026 (Item 2.02) to announce its financial results for the quarter ended June 30, 2026.
• The company furnished a press release reporting those quarterly results as Exhibit 99.1 to the 8-K. The filing was signed by Courtney Phillips, General Counsel and Corporate Secretary.

Key Details

• Filing date: August 11, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Exhibit included: 99.1 — Press release announcing the financial results (dated August 11, 2026).
• Interactive XBRL cover page included (Exhibit 104).

Why It Matters

• This 8-K gives investors the company’s latest quarterly results and related disclosures, which are used to evaluate Maze’s recent operating performance, revenue trends, cash position and progress against milestones.
• The 8-K itself points investors to the press release (Exhibit 99.1) for the detailed figures and management commentary; review that release and any accompanying financial statements for specifics on earnings, revenue, and guidance.